Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Abdelrahman H"'
Autor:
Qingsong Gao, Sarra L Ryan, Ilaria Iacobucci, Pankaj S Ghate, Ruth E Cranston, Claire J Schwab, Abdelrahman H. Elsayed, Lei Shi, Stanley B Pounds, Shaohua Lei, Pradyumna Baviskar, Deqing Pei, Cheng Cheng, Matthew Bashton, Paul B Sinclair, David R Bentley, Mark Ross, Zoya Kingsbury, Terena James, Kathryn G Roberts, Meenakshi Devidas, Yiping Fan, Wenan Chen, Ti-Cheng Chang, Gang Wu, Andrew J. Carroll, Nyla A. Heerema, Virginia Valentine, Marcus B Valentine, Wenjian Yang, Jun J. Yang, Anthony V Moorman, Christine J Harrison, Charles G. Mullighan
Publikováno v:
Blood Journal.
Intrachromosomal amplification of chromosome 21 defines a subtype of high-risk childhood acute lymphoblastic leukemia (iAMP21-ALL) characterized by copy number changes and complex rearrangements of chromosome 21. The genomic basis of iAMP21-ALL and t
Autor:
Richard James Marrero, Xueyuan Cao, Huiyun Wu, Abdelrahman H. Elsayed, Jeffery M Klco, Raul C. Ribeiro, Jeffrey E. Rubnitz, Xiaotu Ma, Soheil Meshinchi, Richard Aplenc, E. Anders Kolb, Rhonda E Ries, Todd Alonzo, Stanley B Pounds, Jatinder Kaur Lamba
Publikováno v:
Blood Advances.
Cytarabine arabinoside (Ara-C) has been the cornerstone of AML chemotherapy for decades. Following cellular uptake, it is phosphorylated into its active triphosphate form (Ara-CTP), which primarily exerts its cytotoxic effects by inhibiting DNA synth
Autor:
Jatinder K. Lamba, Richard J Marrero, Abdelrahman H Elsayed, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Susana C. Raimondi, Ching-Hon Pui, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley B. Pounds
Publikováno v:
Blood. 140:1039-1040
Autor:
Jeffrey E. Rubnitz, Lei Wang, Huiyun Wu, Richard J. Marrero, Abdelrahman H Elsayed, Raul C. Ribeiro, Stanley Pounds, Xueyuan Cao, Jatinder K. Lamba
Publikováno v:
Blood. 138:3429-3429
Acute myeloid leukemia (AML) is a heterogeneous disease characterized in part by genetic and epigenetic alterations. Cytarabine arabinoside (Ara-C) has been the cornerstone of chemotherapy treatment for patients diagnosed with AML for decades. Follow
Autor:
Reema Kashif, Vivek M. Shastri, Jatinder K. Lamba, Nam H.K. Nguyen, Roya Rafiee, Biljana Horn, Karna Mangrola, Trisha Larkin, Abdelrahman H Elsayed, Natasha Emanuel
Publikováno v:
Blood. 138:3360-3360
Introduction: Despite cure rates in acute lymphoblastic leukemia (ALL) exceeding 90% in clinical trials, morbidity due to drug toxicities is high. Genetic polymorphisms can influence gene expression and activity, impacting pharmacokinetics and causin
Publikováno v:
Blood. 136:7-7
Introduction: Ara-C (cytarabine), daunorubicin, and etoposide (ADE) remain key chemotherapies used in remission induction and consolidation therapy of pediatric acute myeloid leukemia (pAML). However, multiple drug resistance is a major cause of ther
Autor:
Jatinder K. Lamba, Xueyuan Cao, Susana C. Raimondi, Tanja A. Gruber, Soheil Meshinchi, Jeffrey E. Rubnitz, Huiyun Wu, James R. Downing, Raul C. Ribeiro, Stanley Pounds, Abdelrahman H Elsayed, Rhonda E. Ries
Publikováno v:
Blood. 134:1429-1429
Introduction: Cytarabine, daunorubicin and etoposide (ADE) are commonly used for remission and intensification of pediatric acute myeloid leukemia (AML). However, development of drug resistance is a major cause of treatment failure. In this study, we
Autor:
Jatinder K. Lamba, Roya Rafiee, Chris D. Vulpe, Abdelrahman H Elsayed, Amin Sobh, Abderrahmane Tagmount
Publikováno v:
Blood. 134:2685-2685
Despite the use of intensive chemotherapeutic regimens containing ara-C, daunorubicin and etoposide (ADE), in combination with stem cell transplantation for high-risk group patients, approximately significant patients experience relapse. Resistant an
Autor:
Abdelrahman H Elsayed, Rhonda E. Ries, Mohammed Gbadamosi, Jatinder K. Lamba, Soheil Meshinchi
Publikováno v:
Blood. 134:1401-1401
Background: In September 2017, the FDA announced re-approval of gemtuzumab ozogamicin (GO), a CD33-directed antibody-drug conjugate, for treatment of newly diagnosed and relapsed/refractory AML setting the pace for a new era of personalized therapeut
Autor:
Xueyuan Cao, Susana C. Raimondi, Tanja A. Gruber, Huiyun Wu, Jatinder K. Lamba, James R. Downing, Abdelrahman H Elsayed, Raul C. Ribeiro, Stanley Pounds, Jeffrey E. Rubnitz
Publikováno v:
Blood. 132:290-290
Introduction: Resistance and relapse remain major obstacles in the treatment of acute myeloid leukemia (AML). Pre-existence and persistence of drug resistant leukemia stem cells (LSCs) is considered one of the major causes of relapse. A previous stud